These terms, conditions and agreements (including those incorporated herein by reference, these “Terms of Service”) outline the rules and regulations for the use of websites owned and operated by Numinus Wellness Inc., including any and all pages whether available publicly or requiring a password to access them (collectively, the “Website”).
The following terminology applies to these Terms of Service, Privacy Statement and Disclaimer Notice and all Agreements: “Client”, “you” and “your” refers to you, the person viewing and/or logging on this Website. “Numinus”, “ourselves”, “we”, “our” and “us”, refers to Numinus Wellness Inc. on its own behalf and, where applicable, on behalf of its affiliates and professional corporation or similar entities managed by it. “Party”, “parties”, or “us”, refers to both you and Numinus. “Services” refers to all services offered by Numinus through the Website from time to time, whether paid or unpaid. Any use of the above terminology or other words in the singular, plural, capitalization and/or he/she or they, are taken as interchangeable and therefore as referring to same.
No Medical Advice
This Website and the Content are for informational and educational purposes only. This Website, the Content (including any User Content) is not a substitute for medical, therapeutic, psychological, psychiatric or other professional diagnosis, treatment or oversight typically conducted by trained professionals or other mental health interventions or licensed coaching (“Professional Advice”). Furthermore, communicating with Numinus through this Website or email do not constitute a medical consultation and neither any such communications nor use of this Website and the Content will create a healthcare provider/patient relationship between you and Numinus or otherwise. Please see Disclaimer & Limitation of Liability.
The Website and the Content are not intended for use in emergencies and should not be used for medical or mental health emergencies. If you have an emergency in a territory covered by public services, you must contact the emergency services in your area (911 in North America, 999 in UK and 112 in most of continental Europe) or go to the nearest hospital or health center.
For reference only, we also provide the US suicide hotline number (1-800-784-2433) or the Canadian suicide hotline number (1-833-456-4566). NUMINUS IS NOT RESPONSIBLE OR LIABLE FOR ANY ADVICE, COURSE OF TREATMENT, DIAGNOSIS OR ANY OTHER MISINFORMATION, INFORMATION, SERVICES OR PRODUCTS THAT YOU MAY LEARN ABOUT THROUGH THE APP.
Numinus does not actively or continuously review, monitor or oversee any User Content or messages sent through this Website.
General Information is Not Medical Advice
The general information provided on the Website is for informational purposes only and is not professional medical or mental health advice, diagnosis, treatment, or care, nor is it intended to be a substitute therefor. Always seek the advice of your physician or other qualified mental health provider in your jurisdiction concerning any questions you may have regarding any information obtained from the Website and any medical condition you believe may be relevant to you or to someone else. Never disregard professional medical advice or delay in seeking it because of something you have read on the Website. Always consult with your physician or other qualified healthcare provider before embarking on a new treatment or making changes to your health or mental health routine. Information obtained on the Website is not exhaustive and does not cover all illnesses, physical conditions, or their treatment options.
No Physician-Patient Relationship
The presentation of general information on the Website does not establish a physician-patient or therapeutic relationship between you and Numinus (or any of its affiliates, clinics managed by its affiliates, members of its referral network or health care professionals working in such clinics) and is not intended as a solicitation of individuals to become patients or clients of any of them. This section does not apply to the extent that you are an existing patient use the booking tool on the Website to book an appointment with your healthcare professional, solely to that extent.
If you are not an existing patient and you wish to contact Numinus or its practitioners regarding medical questions or issues or with regard to appointments, accounts, or other questions, please do so by using the booking tool, telephone or mail in the manner set out on the Website. However, booking an initial call will not establish a physician-patient or therapeutic relationship.
Numinus, the Numinus logo and all other Numinus product or service marks are trademarks of Numinus Wellness Inc. All intellectual property, other trademarks, logos, images, product and company names displayed or referred to on or in the App are the property of their respective owners. Nothing grants you any license or right to use, alter or remove or copy such material. Your misuse of the trademarks displayed on the App is strictly prohibited. Numinus will enforce its trademark rights to the fullest extent of the law.
Use of Website
You may access the Website and its Contents for your own personal noncommercial use in Canada or the United States use, subject to these Terms. You acknowledge and agree that the Website, and its contents, are intended only for residents of Canada and the United States.
Copyright & Limited Use License
You agree NOT TO:
Interacting With Numinus on Social Media
Numinus interacts with the public on various social media platforms. Please do not use our social media platforms for requests for medical or any other matter requiring a reply. In order to ensure that your requests are directed to the appropriate clinic or group, please refer to the “Book Now” or Contact Us sections of the Website.
Social media account(s) are public and are not hosted on Numinus servers. Users who choose to interact with Numinus via social media should read the terms of service and privacy policies of these third-party service providers and those of any applications used to access them. Numinus uses Twitter, Instragram, LinkedIn and Facebook. [NTD: Andrea please confirm]
Personal information that you provide to Numinus via social media account(s) is collected to capture conversations (e.g., questions and answers, comments, “likes”, retweets etc.) between you and Numinus. It may be used to respond to inquiries, or for statistical, evaluation and reporting purposes.
By following our social media accounts (by “following,” “liking” or “subscribing”), you can expect to see information about and related to the business of Numinus. Because the servers of social media platforms are managed by a third party, our social media accounts are subject to downtime that may be out of our control. As such, we accept no responsibility for platforms becoming unresponsive or unavailable.
Our decision to “follow”, “favourite” or “subscribe” to another social media account does not imply an endorsement of that account, channel, page or site, and neither does sharing (re-tweeting, reposting or linking to) content from another user.
Our social media accounts and parts of this Website offer an opportunity for users to post and exchange opinions and information (“User Content”). Numinus does not filter, edit, publish or review User Content prior to its posting. User Content do not reflect the views and opinions of Numinus, its agents and/or affiliates. User Content reflect the views and opinions of the person who post their views and opinions. To the extent permitted by applicable laws, Numinus shall not be liable for the User Content or for any liability, damages or expenses caused and/or suffered as a result of any use of and/or posting of and/or appearance of the User Content on this Website or our social media accounts and/or by sharing or reposting on social media. Numinus reserves the right to monitor all User Content and to remove any User Content which can be considered inappropriate, offensive or causes breach of these Terms of Service.
You warrant and represent that:
By posting or uploading Comments, you hereby grant Numinus a non-exclusive license, royalty-free, perpetual, irrevocable, unrestricted, worldwide license to (i) use, reproduce, edit, store, adapt, translate, modify, make derivative works from, transmit, distribute, publicly perform, or display such Comments for any purpose in any and all forms, formats or media; and (ii) to sublicense to third parties the unrestricted right to exercise any of the foregoing rights. In addition to the grant of the above license, you hereby (i) waive all moral rights in your Comments in favour of Numinus; (ii) consent to your name appearing as the contributor of your Comments, where applicable, and to the disclosure and display of such information and any other information which appears in or is associated with your Comments; (iii) acknowledge and agree that Numinus is not responsible for any loss, damage, or corruption that may occur to your Comments; and (iv) acknowledge and agree that your Comments will be non-confidential.
This Section does not apply to inquiries regarding treatment through the Website.
Hyperlinking to this Website or the Content
The following organizations may link to this Website without prior written approval: government agencies; search engines; news organizations; and online directory distributors may link to this Website in the same manner as they hyperlink to the Websites of other listed businesses.
These organizations may link to our home page, to publications or to other Website information so long as the link: (a) is not in any way deceptive; (b) does not falsely imply sponsorship, endorsement or approval of the linking party and its products and/or services; and (c) fits within the context of the linking party’s site. We may consider and approve other link requests from the following types of organizations:
Numinus may approve, in its sole discretion, link requests from these organizations if we decide that: (a) the link would not make us look unfavourably to ourselves or to our accredited businesses; (b) the organization does not have any negative records with us; (c) the benefit to us from the visibility of the hyperlink compensates the absence of Numinus; and (d) the link is in the context of general resource information.
These organizations may link to our home page so long as the link: (a) is not in any way deceptive; (b) does not falsely imply sponsorship, endorsement or approval of the linking party and its products or services; and (c) fits within the context of the linking party’s site. If you are one of the organizations listed in paragraph 2 above and are interested in linking to this Website, you must inform us by sending an e-mail to Numinus. Please include your name, your organization name, contact information as well as the URL of your site, a list of any URLs from which you intend to link to this Website, and a list of the URLs on our site to which you would like to link. Wait 2-3 weeks for a response.
Approved organizations may hyperlink to this Website as follows:
No use of Numinus’ logo or other artwork will be allowed for linking absent a trademark license agreement.
Without prior approval and written permission, you may not create frames around our webpages that alter in any way the visual presentation or appearance of this Website.
Content Liability for Linked Websites and User Content
We shall not be hold responsible for any User Content or for any content that appears on a website that is linked to this Website. You agree to protect and defend us against all claims that is rising on your User Content or website. No User Contents or link(s) to content should appear on this Website that may be interpreted as libellous, obscene or criminal, or which infringes, otherwise violates, or advocates the infringement or other violation of, any third-party rights. See Disclaimer & Limitation of Liability.
Removal of links or User Content from this Website
Numinus reserves the right to remove any link or User Content of the Website for any reason in our sole discretion.
If you find any link on this Website that is offensive for any reason, you are free to contact and inform us any moment. We will consider requests to remove links, but we are not obligated to or so or to respond to you directly.
Reservation of Rights Regarding Linked Websites
We reserve the right to request that you remove all links or any particular link to this Website. You approve to immediately remove all links to this Website upon request. We also reserve the right to amen these Terms of Service and it’s linking policy at any time. By continuously linking to this Website, you agree to be bound to and follow these linking Terms of Service.
Disclaimer & Limitation of Liability
YOUR USE OF THIS WEBSITE AND THE CONTENT, IS AT YOUR OWN RISK. THIS WEBSITE AND THE CONTENT ARE PROVIDED “AS IS” FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, WE EXCLUDE ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS RELATING TO THIS WEBSITE, THE CONTENT AND THE USE THEREOF.
WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NUMINUS MAKES NO EXPRESS OR IMPLIED REPRESENTATIONS, WARRANTIES OR CONDITIONS, INCLUDING, BUT NOT LIMITED TO: (I) MERCHANTABLE QUALITY OR FITNESS FOR PURPOSE, (II) CYBERSECURITY; (III) NON-INFRINGEMENT; (IV) THAT THIS WEBSITE OR THE CONTENT IS ACCURATE, RELIABLE, UP-TO-DATE, OR COMPLETE; (V) THAT THIS WEBSITE WILL BE COMPATIBLE WITH YOUR NETWORK, HARDWARE OR SOFTWARE; OR (VI) THAT THIS WEBSITE WILL REMAIN AVAILABLE.
AS LONG AS THE WEBSITE, THE CONTENT OR THE SERVICES IN QUESTION MADE AVAILABLE ON OR THROUGH THE WEBSITE ARE PROVIDED FREE OF CHARGE, WE WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE OF ANY NATURE WHATSOEVER.
IN NO EVENT WILL NUMINUS BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR MONETARY LOSS OR DAMAGES, INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUES, BUSINESS INTERRUPTION, LOSS OF INFORMATION OR DATA, DAMAGE TO GOODWILL IN CONNECTION WITH, ARISING OUT OF OR RELATED TO YOUR USE OF THIS WEBISTE OR THE CONTENT OR THE CONTENT OF ANY LINKED WEBSITE.
The limitations and prohibitions of liability set in this section and elsewhere in this disclaimer: (a) are subject to the preceding paragraphs; and (b) govern all liabilities arising under the disclaimer, including liabilities arising in contract, in tort and for breach of statutory duty. Nothing in this disclaimer will:
You agree to indemnify, defend, and hold harmless the Numinus, its affiliates and companies managed by them from and against any and all claims, demands, liabilities, costs, or expenses whatsoever, including, without limitation, legal fees and disbursements, resulting directly or indirectly from (i) your breach of any of the terms and conditions of this Agreement; (ii) your access to, use, misuse, reliance upon, or inability to access or use the Website, the Content, or any Website to which the Website is or may be linked to from time to time; or (iii) your use of, reliance on, publication, communication, distribution, uploading, or downloading of anything (including the Content) on or from the Website.
There are a number of contraindications, risks and serious side effects associated with psychedelic medications. Before considering any medication, consult a healthcare professional as medications may have risks and side effects that vary from person to person.
Tell the doctor right away if you notice worsening depression/other psychiatric conditions, unusual behavior changes (including possible suicidal thoughts/attempts), or other mental/mood changes (including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech).
These disclaimers (and other website content) do not cover all potential side effects, interactions, or contraindications. Where applicable, please refer to the medication's official prescribing information. Always consult a physician or qualified health professional on any matters regarding your mental health or on any opinions expressed within this website or any website or articles linked to it. See “General Information is Not Medical Advice” above.
Numinus does not advocate for, recommend, or otherwise encourage or facilitate access to illegal drugs or treatments, whether decriminalized or not, or unregulated/grey market drugs or treatments.
Spravato® (a form of esketamine) is approved by health Canada and the FDA for treatment resistant depression. When delivered intravenously or as a lozenge, ketamine is used “off label” meaning that neither Health Canada nor the FDA have approved its use to treat mental health conditions. Ketamine is a narcotic and a prescription is required to obtain it.
Common side of ketamine effects of ketamine include dizziness, nausea and vomiting. Ketamine raises heart rate and blood pressure, which can increase the risk of stroke or heart attack. People under the influence of ketamine may have difficulty standing up and be confused about their surroundings. Ketamine can cause vivid dreams or hallucinations, which may be intense and terrifying, and a feeling like the mind is separated from the body. Ketamine has been reported to cause apnea and respiratory depression as well as laryngospasm. Like all anesthetics, ketamine prevents users from feeling pain and, if injury occurs, a person may not know it. Frequent use of ketamine may cause bladder problems. Ketamine can cause psychosis and seizures. Ketamine can be addictive and has a risk for abuse and physical and psychological dependence. The side effects above are not the only effects that you may experience. In addition, there can be various other side effects including, in rare cases, death.
MDMA is not approved by Health Canada or the FDA to treat any indication.
Side effects include feelings of euphoria, increased energy, intimacy and emotional warmth, sensitivity to touch, and a distortion of time and of the senses. Common adverse effects include: jaw clenching or teeth grinding; sweating, thirst, and nausea; and restlessness, insomnia, irritability, anxiety, and impulsiveness. MDMA can interfere with the body’s ability to regulate temperature, and it can raise heart rate, blood pressure, and body temperature. These stimulant effects can result in unpredictable and serious physical complications. These can lead to liver, kidney, or heart failure, and even death. Deaths from MDMA use mostly result from hyperthermia, or a sudden increase in body temperature, cardiovascular collapse, or significant dehydration. Although the effects of MDMA typically last for 3 to 6 hours, adverse after-effects can be felt for a week or more.
MDMA is a controlled substance on Schedule 1 of the Controlled Drugs and Substances Act (Canada) and on Schedule II of the Controlled Substances Act (United States). MDMA has the potential for addiction and persons who take a moderate amount may experience withdrawal-type side effects a week.
Psilocybin is not approved by Health Canada or the FDA to treat any indication.
The effects of psilocybin include altered perception of time and space and intense changes in mood and feeling. Other possible effects include euphoria, derealization; or the feeling that surroundings are not real; depersonalization; distorted thinking; visual alteration and distortion; dizziness; impaired concentration; muscle weakness and lack of coordination; unusual body sensations; nausea and vomiting; paranoia; confusion and frightening hallucinations.
The effects of psilocybin vary between people and side effects are effected by the user’s mental state, personality, and immediate environment. Psychological distress, extreme anxiety or short-term psychosis are a potential adverse effects of psilocybin. Some people who take psilocybin experience persistent, distressing alterations to how they see the world. These may take the form of a visual flashback, a traumatic recall of an intensely upsetting experience. Some individuals who use psilocybin may also experience fear, agitation, confusion, delirium, psychosis, and syndromes that resemble schizophrenia.
According to the National Institute on Drug Abuse, people can continue to experience flashbacks anywhere from weeks to years after using the hallucinogen. This is a condition called hallucinogen-persisting perception disorder and is rare.
Psilocybin is a controlled substance on Schedule 3 of the Controlled Drugs and Substances Act (Canada) and on Schedule I of the Controlled Substances Act (United States). After several days of psilocybin use, individuals might psychological withdrawal and have difficulty adjusting to reality. Regular use may also cause an individual to become tolerant to the effects of psilocybin.
Neither Health Canada nor the FDA have approved the use of cannabis as a treatment for any medical condition, although cannabis-derived and synthetic cannabis-related drug products have been approved for certain indications. Cannabis is legally available for purchase in Canada, it remains heavily regulated under the Cannabis Act (Canada).
Possible side effects of medical cannabis may include: increased heart rate; dizziness; impaired concentration and memory; slower reaction times; increased risk of heart attack and stroke; increased appetite; and hallucinations or the exacerbation or onset of certain mental illness such as delirium, psychosis, and syndromes that resemble schizophrenia. Cannabis has the potential for addiction and regular use can result in tolerance and withdrawal symptoms.
Educational and Opinion Disclaimers
Articles, news, blogs, podcasts and other content on and linked to this website is provided for educational and informational purposes only and does not constitute medical or mental health advice. Research is subject to change and interpretation. Any opinions or conclusion expressed on this website are the opinions of the researchers, authors or persons being interviewed and/or quoted and are not necessarily the opinions of Numinus or general sentiment of the medical profession. Always seek the advice of your own physician and/or mental health practitioner regarding any questions or concerns you have about your specific circumstances. Please refer to “General Information is Not Medical Advice” and “No Physician-Patient Relationship” above.
Some medications discussed on this website are offered on an “off-label” basis, meaning neither Health Canada nor the FDA have approved them to treat any mental health conditions. Other medications on this website are strictly controlled substances, which are not available for prescription or dispensing outside of a controlled clinical trial approved by the FDA or Health Canada or pursuant to an exemption for compassionate grounds under Health Canada regulations. Many of these drug have serious side effects and risks. Please refer to “Medical Disclaimer” above.
Training and Course Disclaimer
Training materials and content are provided for educational and informational purposes only and do not constitute medical or mental health advice. Research and the understanding of treatment benefits and modalities is subject to change and interpretation. Any opinions or conclusion expressed in training are the opinions of the trainers or persons being quoted and are not necessarily the opinions of Numinus or general sentiment of the medical profession.
Training dates and content are subject to change. Timing and/or availability of course seats in a particular Certification Pathway cohort is not guaranteed. Legal availability of experiential component of training cannot be guaranteed, nor can the appropriateness of such experiential training for a given trainee be guaranteed. Completion of a Numinus Certification Pathway may not affect a trainee’s standing, business, or profile.
These Terms of Service, including any agreements incorporated by reference herein or therein, form the entire agreement between the parties with respect to the subject matter hereof. Headings and captions of the sections are for reference only. Numinus holds the benefit of these Terms of Service in trust for its affiliates, subsidiaries and any professional corporations or similar entities managed by Numinus and enforce these Terms of Service on their behalf. Professional Services and paid educational Services offered by Numinus and/or its software applications may be subject to Additional Terms. Please refer to your agreement related to such professional or paid educational Services or the software terms and conditions.
The parties hereby agree that these Terms of Service and any legal relationship between them as well as the resolution of any and all disputes arising therefrom or relating thereto shall be governed by the laws of the Province of British Columbia and the laws of Canada applicable therein (“Jurisdiction”) and that any complaint, demand, claim or cause of action whatsoever shall be subject to the exclusive and preferential jurisdiction of the courts of the Jurisdiction. This clause may not apply in all jurisdictions (which may include Quebec).
Numinus’ failure to insist on or enforce strict performance of any provision of these Terms of Service shall not be construed as a waiver of any provisions or right. If any of the provisions contained in these Terms of Service are determined to be void, invalid or for any reason unenforceable by a court of competent jurisdiction, the remaining provisions contained herein shall continue to apply and these Terms of Service shall be construed to enforce the remaining provisions to the fullest extent possible, and the remainder of these Terms of Service shall continue in full force and effect.
This Terms of Service does not create any agency, partnership, joint venture, employee-employer or franchisor-franchisee relationship between Numinus and you. You may not transfer your rights under these Terms of Service. These Terms of Service will inure to the benefit of and be binding upon the parties, their permitted successors and permitted assignees. Numinus may assign any rights under these Terms of Service to an affiliate, subsidiary or any third party without your consent.